Causes of venous thrombosis in fifty Chinese patients

American Journal of Hematology

Volumn 63, Issue 2, 2000, Pages 74-78

  Ho, Chao Hung ^a,b   Chau, Wing Keung ^a,b   Hsu, Hui Chi ^a,b   Gau, Jyh Pyng ^a,b   Yu, Tarng Jenn ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Chinese population; Deep vein thrombosis; Etiology; Thromboembolism

Indexed keywords

ADULT; AGED; ARTICLE; CANCER; CHINESE; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN S DEFICIENCY; THROMBOGENESIS; VEIN THROMBOSIS;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITHROMBIN III DEFICIENCY; CHINA; FACTOR VIII; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LUNG NEOPLASMS; LYMPHOMA, FOLLICULAR; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; PLASMINOGEN; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RISK FACTORS; STOMACH NEOPLASMS; VENOUS THROMBOSIS;

EID: 0033979365     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(200002)63:2<74::AID-AJH3>3.0.CO;2-V     Document Type: Article

References (45)

1. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci 1993;90:1004-1008.
2. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67.
3. 506 to Gln mutation in the factor V gene, and venous thrombosis. Thromb Haemostas 1995;73: 739-742.
4. Hajjar KA. Factor V Leiden - An unselfish gene? N Engl J Med 1994; 331:1585-1587.
5. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-1134.
6. Dahlback B. Molecular genetics of venous thromboembolism. Ann Med 1995;27:187-192.
7. Ho CH. Prevalence of activated protein C resistance in the Chinese population. Thromb Res 1997;88:409-412.
8. 506-Gln mutation of factor V gene. Thromb Haemostas 1996;75:522-523.
9. Chan CW, Hoaglund FT. Pulmonary thromboembolism and venous thrombosis in Chinese. Clin Orthop 1980;50:253-260.
10. Cheng KK, Lai ST, Yu TJ, Duo SM. Postoperative deep vein thrombosis in the Taiwanese Chinese population. Am J Surg 1987;153:302-305.
11. Woo KS, Tse LKK, Tse CY, Metreweli C, Vallance-Owen J. The prevalence and pattern of pulmonary thromboembolism in the Chinese in Hong Kong. Int J Cardiol 1988;20:373-380.
12. Ho CH, Jap TS. Fibrinolytic activity in Chinese patients with diabetes or hyperlipidemia in comparison with healthy controls. Thromb Haemostas 1991;65:3-6.
13. Ho CH, Jap TS. Relationship of plasminogen activator inhibitor-1 with plasma insulin, glucose, triglyceride and cholesterol in Chinese patients with diabetes. Thromb Res 1993;69:271-277.
14. Ho CH, Chwang LC, Hwang BH. The influence of race on the fibrinolytic activity. J Med Sci 1993;13:349-354.
15. Chakrabarti M, Bielawiec JF, Evans JF, Fearnley GR. Methodological study and a recommended technique for determining the euglobulin lysis time. J Clin Pathol 1968;21:698-701.
16. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-3703.
17. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuvel LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10: 111-113.
18. Buffone GJ, Darlington GJ. Isolation of DNA from biological specimens without extraction with phenol. Clin Chem 1985;31:164-165.
19. Ho CH, Chau WK, Hsu HC, Gau JP, Chin CM. Prevalence of factor V Leiden in the Chinese population. Chin Med J (Taipei) (in press).
20. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995;345:152-155.
21. O'Donnell J, Tuddenham EGD, Manning R, Kemball-Cook G, Johnson D. Laffan M. High prevalence of elevated factor VIII levels in patients referred for thrombophilia Screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemostas 1997;77:825-828.
22. Sorensen HT, Mellemkjar L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. New Engl J Med 1998;338:1169-1173.
23. Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M. Venous thromboembolism and cancer. Lancet 1998;351:1077-1080.
24. Buller H, TenCate JW. Primary venous thromboembolism and cancer screening. New Engl J Med 1998;338:1221-1222.
25. Much JR, Herbst KD, Rapaport SI. Thrombosis in patients with the lupus anticoagulant. Ann Intern Med 1980;92:156-159.
26. Boey ML, Colaco CB, Gharavi A, Elkon K, Liozou S, Hughes GRV. Thrombosis in systemic lupus erythematosus: Striking association with the present of circulation lupus anticoagulant. Br Med J 1983; 287:1021-1023.
27. Triplett DA. Antiphospholipid antibodies and thrombosis. A consequence, coincidence or cause? Arch Pathol Lab Med 1993;117:78-88.
28. Kroger K, Rudofsky G. Duplex sonography of venous stasis. Angiology 1997;48:523-527.
29. Ikeda M, Kambayashi J, Iwamoto S, Shinoki N. Nakamura T, Shibuya T, Kawasaki T, Monden M. The coagulofibrinolytic state of patients with primary varicose veins of the lower legs. Surg Today 1996;26: 985-989.
30. Shen MC, Lin JS, Tsay W. High prevalence of antithrombin III, protein C and protein S deficiency, but no factor V Leiden mutation in venous thrombophilic Chinese patients in Taiwan. Thromb Res 1997; 87:377-385.
31. Bertina RM. Factor V Leiden and other coagulation factor mutations affecting thrombotic risk. Clin Chem 1997;43:1678-1683.
32. Allaart CF, Briet E. Familial venous thrombophilia. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, editors. Haemostasis and thrombosis. Edinburgh: Churchill Livingstone; 1994. 1349-1360.
33. Dolan G, Preston FE. Familial plasminogen deficiency and thromboembolism. Fibrinolysis 1988;2(Suppl 2):26-34.
34. Vinazzer H, Stocker K. Heparin cofactor II: Experimental approach to a new assay and clinical results. Thromb Res 1991;61:235-241.
35. Lin JS, Shen MC, Tsay W. The mutation at position 20210 in the 3′-untranslated region of the prothrombin gene is extremely rare in Taiwanese Chinese patients with venous thrombophilia [letter]. Thromb Haemostas 1998;80:343.
36. Selhub J, Miller JW. The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 1991;55:131-138.
37. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;93:7-9.
38. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-1057.
39. Schwartz SM, Siscovick DS, Malinow MR, Rosendaal FR, Beverly RK, Hess DL, Psaty BM, Longstreth WTJ. Koepsell TD, Raghunathan TE, Reitsma PH. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation 1997;96:412-417.
40. Gaussem P, Siguret V, Aiach M. Evaluation of hemostasis in venous thromboembolism pathology (in French). Ann Biol - Paris 1998;56: 49-56.
41. Reinhardt D, Sigusch HH, Vogt SF, Farker K, Muller S, Hoffmann A. Absence of association between a common mutation in the methylenetetrahydrofolate reductase gene and the risk of coronary artery disease. Eur J Clin Invest 1998;28:20-23.
42. Verhoef P, Rimm EB, Hunter DJ, Chen J, Willett WC, Kelsey K, Stampfer MJ. A common mutation in the methylenetetrahydrofolate reductase gene and risk of coronary heart disease: results among U.S. men. J Am Coll Cardiol 1998;32:353-359.
43. Tosetto A, Missiaglia E, Frezzato M, Rodeghiero F. The VITA project: C677T mutation I the methylene-tetrahydrofolate reductase gene and risk of venous thromboembolism. Br J Haemotal 1997;97:804-806.
44. Cattaneo M, Tsai MY, Bucciarelli P, Taioli E, Zighetti ML, Begnell M, Mannucci PM. A common mutation in the methylenetetrahydrofolate reductase gene (C677T) increases the risk for deep-vein thrombosis in patients with mutant factor V (factor V:Q506). Arterioscl Thromb Vas 1997;17:1662-1666.
45. Kluijtmans LA, van Den Heuvel LP, Boers GH, Frosst P, Stevens EM, van Oost BA, den Heijer M, Trijbels FJ, Rozen R, Blom HJ. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996;58:17-20.